Immunome : Corporate Presentation

Harnessing the Human

Memory B Cell Response

To Develop Antibody- Based Therapeutics

October 25, 2021

Immunome, Inc.

665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com

Copyright © 2021 Immunome, Inc. All rights reserved.

Disclaimers and Forward-Looking Statements

This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation,

express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and COVID-19 therapeutic antibody programs, execution of our regulatory, clinical and strategic plans, anticipated upcoming milestones for IMM- BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; our ability to execute on our strategy with respect to our R&D efforts, IND submissions and other regulatory filings, timing of these filings and governmental authority feedback regarding the same, initiation of clinical studies, generation of clinical data and other anticipated milestones as and when anticipated; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates; our ability to fund operations; our reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in our filings and reports with the SEC. Forward-looking statements contained in this document are made as of this date, and we undertake no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

This document may contain product names, trade names, trademarks and service marks of the Company and of other organizations, of which are the properties of their respective owners.

Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agencies and publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.

We may make statements or predictions about future dates for achievement of milestones related to our programs. These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

Copyright © 2021 Immunome, Inc. All rights reserved.	2

Experienced Management Team

	Purnanand Sarma, PhD	Former CEO of Taris Biomedical
	President & CEO	Sold to Johnson & Johnson in
		2019
	Corleen Roche	Former US CFO Biogen
	Chief Financial Officer	Former CFO, Global Vaccines, Wyeth/Pfizer
	Dennis Giesing, PhD	Former CSO at Taris Biomedical
	Chief Development Officer	Led BARDA funded pandemic flu program at MediVector
	Sandra Stoneman, Esq.	Former Partner at Duane Morris
	Chief Legal Officer	Life Sciences practice group leader
	Mike Morin, PhD	Oversaw cancer, immunology and anti-bacterial
	Chief Scientist	drug discovery at Pfizer
	Matthew Robinson, PhD	Antibody Structure Function Expert
	SVP, Research & Development	formerly at Fox Chase Cancer Center

Copyright © 2021 Immunome, Inc. All rights reserved.	3

Immunome

"At A Glance"

Proprietary Discovery Engine

Rapid, Unbiased Interrogation of Patient Memory B Cells

Applicable Across Multiple Therapeutic Areas

ADVANCING CLINICAL PROGRAMS

IMM-BCP-01 Treatment of COVID-19

• Three antibody cocktail
• Binds to three non-overlapping regions of the spike protein
• ACE2 and Non ACE2 dependent neutralization
• Potent Effector Function - potential for viral clearance

IMM-ONC-01 Treatment of Solid Tumors: Targeting IL-38

• Reverses IL-38 induced dampening of anti-tumor immunity
• IL38 is a novel innate immune checkpoint
• Potential indications include Lung, Head & Neck, Melanoma

ROBUST PIPELINE

• Multiple target rich areas of cancer biology
• • Membrane Dynamics/Exosomes
  • Antibody Drug Conjugates (ADCs)
• Anti-infectives
• • Rapid Response to new infections/outbreaks

Copyright © 2021 Immunome, Inc. All rights reserved.

IND Submission Q4 2021 Topline Data H1 2022

IND submission Q1 2022

Potential for multiple new programs and partnerships

4

Immunome Development Pipeline and Anticipated Key Milestones

ANTI-INFECTIVES	TARGET	PRODUCT CANDIDATE	DISCOVERY	PRECLINICAL	ANTICIPATED
DESCRIPTION	MILESTONE

IMM-BCP-01	Three SARS-	Three antibody	IND filing Q4 2021
CoV-2 Epitopes	cocktail

ONCOLOGY	TARGET	PRODUCT CANDIDATE	DISCOVERY	PRECLINICAL	ANTICIPATED
DESCRIPTION	MILESTONE

IMM-ONC-01	IL-38	Anti IL-38 antibody			IND filing Q1 2022

Copyright © 2021 Immunome, Inc. All rights reserved.	5